News Standigm agrees partnership with KIST to discover a new drug for Autism

September 13, 2017

Standigm and Korea institute of science and technology (KIST) announced a research collaboration to develop a new small molecule medicine for Autism. The drug candidates chosen by Standigm’s AI drug discovery technology will validate experimentally by using KIST’s animal models.

News CrystalGenomics, a partner biopharmaceutical company of Standigm, finds first evidence to a new AI-driven drug for cancer.

August 29, 2017

CrystalGenomics, Inc., Standigm’s partner company, today announced a drug predicted by Standigm’s artificial intelligence technology showed the evidence that it may reuse for cancer treatment. The drug is an FDA-proved drug for other therapeutic uses. It has been only three months to sign the partnership between Standigm, Inc. and CrystalGenomics, Inc.

Press Report highlights 6 AI startups in healthcare.

June 22, 2017

Seoul, Korea, South, June 22, 2017 - The advent of artificial intelligence (AI) has global pharmaceutical companies and startups in a race to develop new products and services in all sectors. The field of healthcare is no exception with the U.S. leading the way in AI startups. Many startups partner with bigger companies or become part of the latter. The National Information Society Agency released a report Tuesday on promising AI startups in Korea, including six in the field of healthcare – Neofect, Vuno, Tomocube, Lunit, Standigm, and Bitfinder.